Aug 10, 2023
Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Rheumatoid Arthritis: A Protocol for a Systematic Review
- Andriko Palmowski1,
- Judith Oldenkott1,
- Anne Pankow1,
- Anne Beenken1,
- Eric L Matteson2,
- Frank Buttgereit1
- 1Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Germany;
- 2Mayo Clinic, Rochester, Minnesota, United States of America
Protocol Citation: Andriko Palmowski, Judith Oldenkott, Anne Pankow, Anne Beenken, Eric L Matteson, Frank Buttgereit 2023. Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Rheumatoid Arthritis: A Protocol for a Systematic Review. protocols.io https://dx.doi.org/10.17504/protocols.io.bp2l6x955lqe/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: August 10, 2023
Last Modified: August 10, 2023
Protocol Integer ID: 86324
Keywords: associated adverse events in rheumatoid arthritis, rheumatoid arthritis, investigating glucocorticoid, associated adverse event, systematic review, indication in observational study
Abstract
-
Abstract
Background Glucocorticoids (GCs) are regularly used drugs in rheumatoid arthritis (RA), but they can cause adverse events (AEs). Observational studies provide important real-world evidence but can be biased. Observational studies investigating the association between AEs and GCs in RA are
particularly susceptible to confounding by indication as patients with higher disease activity are more likely to suffer from AEs and more likely to receive GCs.
Objective To assess how often observational studies in RA which investigate the association between GCs and certain AEs adjust for disease activity (such as the disease activity score-28 joints) and/or systemic inflammation (such as serum C-reactive protein levels).
Methods A systemic literature review will be conducted and reported in compliance with the 2020 PRISMA statement.
PDF Protocol
Protocol.pdf211KB